drugset / Trial / NCT02762812
Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis
RandomizedParallel-groupTriple-blindTreatment
Summary
BCD-055-2 is international multi-center comparative double-blind randomized clinical trial to evaluate efficacy and safety of BCD-055 (JSC "BIOCAD", Russia) and Remicade® in patients with ankylosing spondylitis. BCD-055 is biosimilar of infliximab (JSC "BIOCAD", Russia)
Timeline
- Start
- 2016-01
- Primary completion
- 2017-05
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCD-055 | Unknown | 5 mg/kg | — |
| Comparator | Infliximab | Monoclonal antibody | 5 mg/kg | — |